195 related articles for article (PubMed ID: 38588984)
21. A novel fatty acid mimetic with pan-PPAR partial agonist activity inhibits diet-induced obesity and metabolic dysfunction-associated steatotic liver disease.
Sahin C; Melanson JR; Le Billan F; Magomedova L; Ferreira TAM; Oliveira AS; Pollock-Tahari E; Saikali MF; Cash SB; Woo M; Romeiro LAS; Cummins CL
Mol Metab; 2024 Jul; 85():101958. PubMed ID: 38763495
[TBL] [Abstract][Full Text] [Related]
22. The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).
Wang Z; Li S; Wang R; Guo L; Xu D; Zhang T; Xu Y; Wang W; Wang M; Gan Z; Wang X
Mol Med; 2020 Jun; 26(1):54. PubMed ID: 32503411
[TBL] [Abstract][Full Text] [Related]
23. Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway.
Li Q; Tan JX; He Y; Bai F; Li SW; Hou YW; Ji LS; Gao YT; Zhang X; Zhou ZH; Yu Z; Fang M; Gao YQ; Li M
Int J Biol Sci; 2022; 18(4):1594-1611. PubMed ID: 35280674
[No Abstract] [Full Text] [Related]
24. Vitexin alleviates non-alcoholic fatty liver disease by activating AMPK in high fat diet fed mice.
Inamdar S; Joshi A; Malik S; Boppana R; Ghaskadbi S
Biochem Biophys Res Commun; 2019 Oct; 519(1):106-112. PubMed ID: 31472955
[TBL] [Abstract][Full Text] [Related]
25. Salidroside and Curcumin Formula Prevents Liver Injury in Nonalcoholic Fatty Liver Disease in Rats.
Li HS
Ann Hepatol; 2018 Aug; 17(5):769-778. PubMed ID: 30145577
[TBL] [Abstract][Full Text] [Related]
26. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
27. Ping-tang Recipe () improves insulin resistance and attenuates hepatic steatosis in high-fat diet-induced obese rats.
Yang SY; Zhao NJ; Li XJ; Zhang HJ; Chen KJ; Li CD
Chin J Integr Med; 2012 Apr; 18(4):262-8. PubMed ID: 22457136
[TBL] [Abstract][Full Text] [Related]
28. Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway.
Zhang YP; Deng YJ; Tang KR; Chen RS; Liang S; Liang YJ; Han L; Jin L; Liang ZE; Chen YN; Yang QH
Curr Med Sci; 2019 Feb; 39(1):37-43. PubMed ID: 30868489
[TBL] [Abstract][Full Text] [Related]
29. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
Xiao Z; Chu Y; Qin W
Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
[TBL] [Abstract][Full Text] [Related]
30. Tartaric acid ameliorates experimental non-alcoholic fatty liver disease by activating the AMP-activated protein kinase signaling pathway.
Pei Y; He Y; Wang X; Xie C; Li L; Sun Q; Liu L; Shan S; Wang P; Liu T; Fan X; Cong M; Jia J
Eur J Pharmacol; 2024 Jul; 975():176668. PubMed ID: 38788791
[TBL] [Abstract][Full Text] [Related]
31. Mangiferin Ameliorates HFD-Induced NAFLD through Regulation of the AMPK and NLRP3 Inflammasome Signal Pathways.
Yong Z; Ruiqi W; Hongji Y; Ning M; Chenzuo J; Yu Z; Zhixuan X; Qiang L; Qibing L; Weiying L; Xiaopo Z
J Immunol Res; 2021; 2021():4084566. PubMed ID: 34734090
[TBL] [Abstract][Full Text] [Related]
32. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
Lee MR; Yang HJ; Park KI; Ma JY
Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
[TBL] [Abstract][Full Text] [Related]
33. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.
Han R; Qiu H; Zhong J; Zheng N; Li B; Hong Y; Ma J; Wu G; Chen L; Sheng L; Li H
Phytomedicine; 2021 May; 85():153544. PubMed ID: 33773192
[TBL] [Abstract][Full Text] [Related]
34. High-altitude chronic hypoxia ameliorates obesity-induced non-alcoholic fatty liver disease in mice by regulating mitochondrial and AMPK signaling.
Song K; Zhang Y; Ga Q; Bai Z; Ge RL
Life Sci; 2020 Jul; 252():117633. PubMed ID: 32289432
[TBL] [Abstract][Full Text] [Related]
35. Protopanaxadiol ameliorates NAFLD by regulating hepatocyte lipid metabolism through AMPK/SIRT1 signaling pathway.
Li Y; Liu Y; Chen Z; Tang K; Yang L; Jiang Y; Wang J; Huang P; Wang J; Zheng P; Song H
Biomed Pharmacother; 2023 Apr; 160():114319. PubMed ID: 36724639
[TBL] [Abstract][Full Text] [Related]
36. Linalool attenuates lipid accumulation and oxidative stress in metabolic dysfunction-associated steatotic liver disease via Sirt1/Akt/PPRA-α/AMPK and Nrf-2/HO-1 signaling pathways.
Tamilmani P; Sathibabu Uddandrao VV; Chandrasekaran P; Saravanan G; Brahma Naidu P; Sengottuvelu S; Vadivukkarasi S
Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102231. PubMed ID: 37865226
[TBL] [Abstract][Full Text] [Related]
37. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
38. Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota.
Chen L-p; Zhang L-f; Liu S; Hua H; Zhang L; Liu B-c; Wang R-r
Microbiol Spectr; 2024 Jun; 12(6):e0197923. PubMed ID: 38647315
[TBL] [Abstract][Full Text] [Related]
39. An unbiased lipidomics approach identifies key lipid molecules as potential therapeutic targets of Dohongsamul-tang against non-alcoholic fatty liver diseases in a mouse model of obesity.
Park SH; Lee JE; Lee SM; Lee J; Seo CS; Hwang GS; Jung J
J Ethnopharmacol; 2020 Oct; 260():112999. PubMed ID: 32454173
[TBL] [Abstract][Full Text] [Related]
40. Chaperonin counteracts diet-induced non-alcoholic fatty liver disease by aiding sirtuin 3 in the control of fatty acid oxidation.
Weng SW; Wu JC; Shen FC; Chang YH; Su YJ; Lian WS; Tai MH; Su CH; Chuang JH; Lin TK; Liou CW; Chu TH; Kao YH; Wang FS; Wang PW
Diabetologia; 2023 May; 66(5):913-930. PubMed ID: 36692509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
